A review on cyclin-dependent kinase 5: An emerging drug target for neurodegenerative diseases

Area of Science:

• Neuroscience
• Molecular Biology
• Pharmacology

Background:

• Cyclin-dependent kinase 5 (CDK5) is a key kinase in the central nervous system, vital for neuronal development.
• Dysregulation of CDK5, particularly through p25 and p29, contributes to tau hyperphosphorylation, a hallmark of neurodegenerative diseases.

Purpose of the Study:

• To review the multifaceted roles of CDK5 in neuronal functions, including synaptic plasticity and DNA repair.
• To analyze the structural characteristics of CDK5 and its inhibitors for therapeutic strategy development.
• To elucidate the potential of CDK5 inhibitors in managing neurodegenerative disorders.

Main Methods:

• Extensive literature analysis of CDK5's function and involvement in neurological diseases.
• Investigation of CDK5 structural features and inhibitor binding modes.
• Review of existing and potential therapeutic strategies targeting CDK5.

Main Results:

• CDK5 plays critical roles in neuronal development, synaptic plasticity, DNA repair, and cell cycle regulation.
• Proteolytic products of CDK5 activators (p25, p29) are implicated in tau hyperphosphorylation.
• Various high-affinity CDK5 inhibitors, including Roscovitine, are being explored for symptom management.

Conclusions:

• CDK5 inhibitors offer significant therapeutic potential for neurodegenerative diseases.
• Understanding CDK5 structure-inhibitor interactions is key to developing effective treatments.
• Further research into CDK5 inhibition can advance clinical management of neurological conditions.